Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

GP training may ease long COVID burden

NCT ID NCT06082258

Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial tests whether training general practitioners to better manage persistent symptoms after COVID-19 can improve patients' quality of life. Adults with at least two long COVID symptoms (like fatigue, breathlessness, or brain fog) lasting over two months will be enrolled. The study compares standard care to a program where GPs receive specialized training and are reimbursed for longer consultations. The main goal is to see if patients report better physical health after three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
training and support intervention for general practitioners
What this could lead to
If effective, this approach could offer a practical way to improve quality of life for people with persistent post-COVID symptoms through better GP care.
What could go wrong
This is a relatively small, early-stage study focused on GP training rather than a direct treatment, so benefits may be modest or not generalizable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Nov 2024

An estimate. Start dates often move.

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * at least two symptoms attributed to COVID-19 (including fatigue, dyspnea, cognitive impairment or pain); persistent for more than 2 months; not explained by a diagnosis unrelated to COVID-19; * a quality of life impairment considered significant by the patient. Exclusion Criteria: * Refusal to participate in the study * Under 18 years of age * Persistent symptoms secondary to an objective sequelae from the initial episode of COVID-19. * Neuropsychiatric disorder that may impair cognitive function prior to COVID-19 * Medical contraindication to physical training (pericarditis or myocarditis...) * Patient not affiliated with the social security system or under AME * Patient under guardianship, guardianship or guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-acute COVID-19 syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-acute COVID-19 syndrome

Contacts and locations

Locations

  • DAC 75

    Paris, 75013, France

  • DAC 92

    Suresnes, 92150, France

  • DAC 93

    Saint-Denis, 93200, France

  • Paris Est (CPTS 12e et 20e)

    Paris, 75012, France

  • Paris Nord (CPTS 10e)

    Paris, 75010, France

  • Paris Ouest (CPTS 15e)

    Paris, 75015, France

  • Paris Sud (CPTS 13-14e)

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.